Organ systems

Defymed Accelerates Its Development in the United States: One Step Closer to Patients

Retrieved on: 
Friday, September 20, 2019
Diabetes, Stem cells, Surgery, Managed care, Medical devices, Hospitals, Clinical trials, Science, Other Science, Research, Health, Diabetes, Organ systems, Medicine, RTT, Medical terminology, Chronic condition, Diabetes management, Diabetic hypoglycemia

This program will allow Defymed to support its international expansion by developing new partnerships in the United States.

Key Points: 
  • This program will allow Defymed to support its international expansion by developing new partnerships in the United States.
  • The company is currently developing two medical devices for the physiological treatment of diabetes and other chronic diseases.
  • In addition, thanks to the Innouvo program, Defymed will be able to accelerate and pursue its expansion into the United States.
  • What is most important is that Defymed is able to bring its solutions to diabetic patients around the world.

AC Immune Receives First Milestone Payment from Lilly in Small Molecule Tau Morphomer™ Program

Retrieved on: 
Friday, September 20, 2019
Branches of biology, Organ systems, Nervous system, Dementia, Psychiatric diagnosis, Neuroscience, Proteins, Tau protein, Alzheimer's disease, Neurodegeneration

Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: Lilly has brought substantial experience in neurology, and particularly in Alzheimers disease, to this collaboration.

Key Points: 
  • Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: Lilly has brought substantial experience in neurology, and particularly in Alzheimers disease, to this collaboration.
  • This milestone payment recognizes that the development of the lead small molecule MorphomerTM in our collaboration, ACI-3024, is progressing.
  • ACI-3024 is the lead molecule being developed in the license and collaboration agreement between AC Immune and Lilly to research and develop small molecule Tau aggregation inhibitors for the treatment of AD and other neurodegenerative diseases.
  • Under the agreement AC Immune is conducting the initial Phase 1 development of the Morphomer Tau aggregation inhibitors while Lilly will fund and conduct additional research and further clinical development.

Cativa CBD Announces PGA Tour Professional Marc Leishman

Retrieved on: 
Thursday, September 19, 2019
Drugs, Cannabinoids, Resorcinols, Leishman, CBD, Cannabidiol, Organ systems

PORTSMOUTH, Va., Sept. 19, 2019 /PRNewswire-PRWeb/ --Cativa Health ("Cativa CBD"), a science-based cannabidiol (CBD) brand set to revolutionize the wellness and CBD industries, announced today that professional golfer Marc Leishman will act as the brand's first celebrity spokesperson.

Key Points: 
  • PORTSMOUTH, Va., Sept. 19, 2019 /PRNewswire-PRWeb/ --Cativa Health ("Cativa CBD"), a science-based cannabidiol (CBD) brand set to revolutionize the wellness and CBD industries, announced today that professional golfer Marc Leishman will act as the brand's first celebrity spokesperson.
  • Mr. Leishman will collaborate with Cativa CBD on a variety of public relations and marketing activities, including promotions, digital and social media campaigns, and events.
  • "We are elated to have Marc represent Cativa CBD as we grow the brand across North America.
  • "When I was introduced to Cativa CBD, I knew I wanted to be a part of their science-based CBD revolution.

Cerevel Therapeutics to Present Results from a Phase 2 Study of Tavapadon in Patients with Early-stage Parkinson’s Disease

Retrieved on: 
Thursday, September 19, 2019
Science, Biotechnology, Pharmaceutical, Research, Health, Clinical trials, Drugs, Branches of biology, Organ systems, Dopamine agonists, Catecholamines, Dopamine, Neurotransmitters, Phenethylamines

Cerevel Therapeutics , a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, will present new data from a Phase 2 clinical trial evaluating tavapadon (formerly PF-06649751) in patients with early-stage Parkinsons disease at the 2019 International Congress of Parkinsons Disease and Movement Disorders , taking place from September 22-26 in Nice, France.

Key Points: 
  • Cerevel Therapeutics , a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, will present new data from a Phase 2 clinical trial evaluating tavapadon (formerly PF-06649751) in patients with early-stage Parkinsons disease at the 2019 International Congress of Parkinsons Disease and Movement Disorders , taking place from September 22-26 in Nice, France.
  • Tavapadon is a novel, investigational, orally-administered, selective partial agonist of the dopamine D1 and D5 receptors.
  • Cerevel Therapeutics has a diversified pipeline comprising four clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinsons, epilepsy, schizophrenia and addiction.
  • Headquartered in Boston, Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Minorities more likely to have diabetes at lower weights

Retrieved on: 
Thursday, September 19, 2019
Organ systems, Medicine, Health, Prediabetes, Body mass index, Diabetes, Epidemiology of diabetes, Epidemiology of metabolic syndrome

Members of racial and ethnic minority groups were much more likely to have diabetes or prediabetes at lower weights even at normal or below-normal body mass index (BMI), according to research published in Diabetes Care.

Key Points: 
  • Members of racial and ethnic minority groups were much more likely to have diabetes or prediabetes at lower weights even at normal or below-normal body mass index (BMI), according to research published in Diabetes Care.
  • Normal-weight Hawaiians and Pacific Islanders were 3 times more likely to have diabetes than normal-weight white people.
  • Asians, Hispanics, and Hawaiians/Pacific Islanders had a higher prevalence of prediabetes at lower BMIs than other groups, particularly among women.
  • This study is one of the largest that has examined the relationship between BMI and diabetes and prediabetes prevalence.

The New England Center for Children Announces Partnership with New School In Lebanon for Children with Autism

Retrieved on: 
Thursday, September 19, 2019
Pervasive developmental disorders, Psychiatry, Abnormal psychology, Autism, Psychiatric diagnosis, RTT, Organ systems, Beirut

One Two Three is the first and only school in Lebanon for children with autism.

Key Points: 
  • One Two Three is the first and only school in Lebanon for children with autism.
  • "NECC is excited to bring proven, research-based ABA teaching practices to Lebanon through our management of One Two Three Autism School.
  • The autism rate for children in Beirut and Mount Lebanon is one in 67," said Saritta Trad, a co-founder and mother whose son attends the school.
  • The New England Center for Children is based in Southborough, MA, and operates a center in Abu Dhabi, UAE.

CureDuchenne Appoints Lianna Orlando, PhD, to the Position of Senior Director of Research

Retrieved on: 
Thursday, September 19, 2019
Research, Biotechnology, Other Health, Pharmaceutical, Health, General Health, Science, Muscular dystrophy, RTT, Organ systems, Duchenne, Dystrophy, Medicine, Health, Draft:CureDuchenne, Muscular Dystrophy Association

CureDuchenne, the leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, announced today that Lianna Orlando, PhD has joined the team as Senior Director of Research.

Key Points: 
  • CureDuchenne, the leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, announced today that Lianna Orlando, PhD has joined the team as Senior Director of Research.
  • In this role, Orlando will help identify and evaluate strategic investments aimed at developing treatments for Duchenne muscular dystrophy.
  • The organization has a stellar reputation for being agile and impactful in its research investments, said Orlando.
  • Before that, she was the Associate Director at Fidelity Biosciences Research Initiative (FBRI), focusing on funding research programs in neurodegenerative diseases.

Context Therapeutics and Jefferson Health to Evaluate Apristor Combination Therapy for Women with Advanced Endometrial Cancer

Retrieved on: 
Thursday, September 19, 2019
Research, Pharmaceutical, Oncology, Consumer, Science, Clinical trials, Women, Biotechnology, Health, Hormones, Organ systems, Clinical medicine, Antiprogestogens, Hepatotoxins, Prolactin releasers, Cancer treatments, Gynaecological cancer, Endometrial cancer, Antiestrogen, Onapristone, Estrogen

This clinical collaboration will evaluate whether the addition of Apristor to the antiestrogen, anastrazole, can enhanced outcomes for patients with metastatic endometrial cancer who have failed multiple prior therapies.

Key Points: 
  • This clinical collaboration will evaluate whether the addition of Apristor to the antiestrogen, anastrazole, can enhanced outcomes for patients with metastatic endometrial cancer who have failed multiple prior therapies.
  • View the full release here: https://www.businesswire.com/news/home/20190919005028/en/
    Context Therapeutics and Jefferson Health to Evaluate Apristor Combination Therapy for Women with Advanced Endometrial Cancer (Graphic: Business Wire)
    The Phase 2 trial will assess an oral treatment consisting of the progesterone receptor antagonist, Apristor (onapristone ER) plus the antiestrogen, anastrazole, in up to 25 patients who are ER+,PR+,HER2- and who have received prior chemotherapy treatment.
  • Currently, there are limited therapeutic options to treat endometrial cancer in the advanced setting.
  • The hormones estrogen and progesterone drive endometrial cancer progression in those patients, but antiestrogens are the only antihormonal therapy available to clinicians.

The neurosurgery devices market is projected to grow at a CAGR of 13.0%

Retrieved on: 
Thursday, September 19, 2019
Branches of biology, Neuroscience, Neurophysiology, Organ systems, Neuromodulation, Neuropsychology, Neurotechnology, Pain, Compound annual growth rate

The neurosurgery devices market is projected to grow at a CAGR of 13.0% during the forecast period.

Key Points: 
  • The neurosurgery devices market is projected to grow at a CAGR of 13.0% during the forecast period.
  • The neurosurgery devices market is projected to reach USD 13.5 billion by 2024 from USD 7.3 billion in 2019, at a CAGR of 13.0% during the forecast period.
  • The internal neuromodulation devices segment accounted for the largest share of the neuromodulation devices market in 2018.
  • On the basis of product, the neurosurgery devices market is segmented into neuromodulation devices and neuroendoscopy devices.The neuromodulation devices market is further segmented into internal neuromodulation devices and external neuromodulation devices.

Dance Biopharm Presents Phase 2 Clinical Data Highlighting Rapid Effects of Inhaled Human Insulin at European Association for the Study of Diabetes Meeting

Retrieved on: 
Thursday, September 19, 2019
Eli Lilly and Company, Medicine, Endocrine system, Organ systems, RTT, Peptide hormones, Recombinant proteins, Insulin, Diabetes, Inhaler, Insulin analog

The data were presented at the 55th Annual Meeting of the European Association for the Study of Diabetes on September 19, 2019, in Barcelona, Spain.

Key Points: 
  • The data were presented at the 55th Annual Meeting of the European Association for the Study of Diabetes on September 19, 2019, in Barcelona, Spain.
  • Study results showed Dance 501 inhaled human insulin (INH) had comparable glucodynamic properties to injected insulin lispro (LIS), but delivered a faster onset of action.
  • This study also further validates our smart inhalers ability to deliver an optimal and precise dose of inhaled therapies through the lungs.
  • The randomized, controlled clinical study evaluated the pharmacodynamic action and safety of Dance 501 inhaled human insulin in comparison to injected insulin lispro in T2D patients.